U.S. Markets close in 2 hrs 7 mins

Digipath Labs Publishes Research on Application of Terpenoid Profiles in Cannabis Classification

LAS VEGAS, Jan. 11, 2018 /PRNewswire/ -- Digipath, Inc. (DIGP) ("DIGP" or the "Company"), a service oriented independent cannabis testing laboratory and media firm focused on the developing cannabis market, today announced that Dr. Cindy Orser, Chief Science Officer at Digipath Labs, recently published original research on the application of terpenoid chemoprofiles for cannabis classification in the peer-reviewed journal, Natural Products Chemistry & Research. This research furthers Digipath's scientific analysis on the importance of terpenoid data for growers and consumers.

DigiPath, Inc., through its subsidiary, DigiPath, Corp., creates and markets innovative and reliable digital pathology solutions that empower private and academic institutions with the ability to create, store, manage, analyze, and correlate data collected through virtual microscopy. DigiPath, Inc. digital pathology portfolio includes PathScope(TM), PathCloud(TM), PathReview(TM), and PathConsult(TM) digital platforms to share and store archive tissue images. DigiPath, Inc. is expanding into new lines of business associated with the research, development, licensing and operation of botanical and nutrapharmaceutical products and services. (PRNewsFoto/Digipath, Inc.)

The detailed chemical database resulting from the analyses of thousands of cannabis flower samples from an artificially geographically restricted area can serve as the basis for the development of a chemotaxonomic classification scheme outside of conjectural cultivar naming by strain. Chemotaxonomic classification schemes for cannabis cultivars have previously been reported by others based largely on cannabis strains grown under an unregulated testing environment or in Europe from strains grown by a single cultivator. In this study 2,237 individual cannabis flower samples, representing 204 individual strains across 27 cultivators in a tightly regulated Nevada cannabis testing market, were analyzed across 11 cannabinoids and 19 terpenoids. Even though 98.3% of the samples were from Type I cannabis strains with high THCA content, principal component analysis (PCA) of the combined chemometric dataset resulted in three distinct clusters that were distinguishable by terpenoid profiles alone.

Dr. Cindy Orser commented, "We propose that three terpenoid cluster assignments account for the diversity of drug-type cannabis strains currently being grown in Nevada. Expanded chemometric datasets will be used to further refine the Digipath terpenoid-centric classification scheme across cannabis cultivars." 

Todd Denkin, President and COO at Digipath Labs, reiterated the company's goal of leveraging terpenoid data by stating, "after years of focusing solely on THCA content, cannabis growers are now paying more attention to the distinctive subtleties that terpenoids contribute."

About Digipath, Inc. (DIGP)

Digipath, Inc., supports the cannabis industry's best practices for reliable cannabis testing and education and brings unbiased cannabis news coverage to the cannabis industry.

Digipath Labs provides pharmaceutical-grade analysis and testing to the cannabis industry to ensure producers, consumers and patients know exactly what is in the cannabis they ingest and to help maximize the quality of its client's products through analysis, research, development, and standardization.

Information about Forward-Looking Statements

This press release contains "forward-looking statements" that include information relating to future events. Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management's good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in, or suggested by, the forward-looking statements. Important factors that could cause these differences include, but are not limited to: the Company's need for additional funding, the demand for the Company's products, governmental regulation of the cannabis industry, the Company's ability to maintain customer and strategic business relationships, the impact of competitive products and pricing, growth in targeted markets, the adequacy of the Company's liquidity and financial strength to support its growth, and other risks that may be detailed from time-to-time in the Company's filings with the United States Securities and Exchange Commission. For a more detailed description of the risk factors and uncertainties affecting Digipath, please refer to the Company's recent Securities and Exchange Commission filings, which are available at www.sec.gov. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Contact
Harrison Phillips
Viridian Capital Advisors, LLC
(212) 209-3086
hphillips@viridianca.com

 

Cision

View original content with multimedia:http://www.prnewswire.com/news-releases/digipath-labs-publishes-research-on-application-of-terpenoid-profiles-in-cannabis-classification-300581250.html